In the last study, 16/16 CR/CRi was observed in patients receiving CD5 KO anti-CD5 CARs, but the trial was halted due to multiple fatal infections in the cohort of patients previously treated with allo-HSCT [235]. This evidence concerns the gene CD5 and infection.